EMA — authorised 11 May 2016
- Marketing authorisation holder: Bristol-Myers Squibb
- Status: approved
EMA authorised Huluc63 on 11 May 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 11 May 2016.
Bristol-Myers Squibb holds the EU marketing authorisation.